ArticleCellular and molecular life sciences : CMLS2026
FOS drives podocyte injury and renal fibrosis in diabetic kidney disease via direct Smad3 binding.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEpithelial-mesenchymal transition (EMT) plays a crucial role in diabetic kidney disease (DKD), particularly in the context of podocyte EMT. However, the regulatory networks controlling EMT activation in podocytes remain incompletely mapped. The FOS proto-oncogene (FOS) has emerged as a key player in EMT, yet its functional significance in DKD-podocytes remains poorly defined.
methodsThe predictive validity of FOS was confirmed through least absolute shrinkage and selection operator (LASSO) regression and multivariable logistic analysis in clinical data. A streptozotocin-induced DKD rat model was established, and podocyte cells (MPC5, HPC) treated with high glucose served as an in vitro model. The functional effect of FOS was explored using genetic interventions in vivo and in vitro.
resultsFOS expression is increased in patients with DKD, correlating with deterioration in renal function. LASSO and logistic analyses identified FOS as a robust predictor of DKD progression. FOS deficiency in vivo attenuated renal dysfunction and fibrosis. In podocytes, high glucose-primed FOS induced EMT and collagen accumulation, effects reversed by FOS knockdown. Crucially, FOS directly bound and activated Smad3, while Smad3 silencing abolished FOS-mediated injury.
conclusionThis study demonstrates that the FOS/Smad3 axis is a critical contributor to coordinating EMT and fibrosis in diabetic renal podocytes, proposing a novel therapeutic target in DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.